导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.46% | 2650/4653 |
| 近一周 | -1.84% | 3444/5325 |
| 近一月 | -6.61% | 3118/5279 |
| 近一季 | -8.35% | 2597/5100 |
| 近半年 | -2.66% | 2350/4806 |
| 近一年 | 1.60% | 2170/4298 |
| 近两年 | 43.94% | 1647/2893 |
| 近三年 | 27.35% | 1144/2196 |
| 成立以来 | 103.46% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.13% 3048/4961 |
13.60% 1983/5312 |
- - |
- - |
| 2025 | 21.47% 2036/4813 |
0.02% 2004/3635 |
1.04% 2488/4076 |
20.04% 2048/4524 |
0.13% 2197/4813 |
| 2024 | 14.77% 1008/3463 |
2.97% 649/2808 |
-0.92% 873/3014 |
16.28% 1492/3129 |
-3.25% 2308/3463 |
| 2023 | -9.81% 1233/2656 |
4.52% 931/2280 |
-4.27% 1118/2385 |
-3.37% 909/2515 |
-6.72% 1892/2655 |
| 2022 | -21.21% 1017/2207 |
-13.44% 760/1919 |
6.67% 638/2016 |
-15.38% 1281/2113 |
0.85% 1441/2208 |
| 2021 | -6.14% 998/1822 |
-2.68% 690/1255 |
2.26% 1009/1330 |
-7.20% 1033/1466 |
1.64% 853/1822 |
| 2020 | 38.43% 360/1250 |
-9.90% 730/1028 |
13.59% 606/1067 |
16.08% 170/1164 |
16.52% 161/1184 |
| 2019 | 40.88% 244/1092 |
25.43% 465/754 |
2.88% 66/804 |
2.45% 299/850 |
6.57% 593/918 |
| 2018 | -18.91% 152/834 |
- - |
- - |
- - |
-11.79% 349/691 |
| 2017 | 33.33% 45/714 |
- - |
- - |
- - |
- - |
| 2016 | -4.59% 160/605 |
- - |
- - |
- - |
- - |
| 2015 | -1.90% 263/575 |
- - |
- - |
- - |
- - |
| 2014 | 59.10% 38/237 |
- - |
- - |
- - |
- - |
| 2013 | -10.70% 160/186 |
- - |
- - |
- - |
- - |
| 2012 | 11.55% 30/140 |
- - |
- - |
- - |
- - |
| 2011 | -19.10% 26/102 |
- - |
- - |
- - |
- - |
| 2010 | -19.00% 51/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 华宝中证A100ETF联接A VS. 长安沪深300非周期A(740101) |